Essex Bio-Technology Limited carried out an on-market share buyback on 16 September 2026, acquiring 25,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HK$2.025 to HK$2.05 per share. The volume-weighted average price was approximately HK$2.039, bringing the total consideration to HK$50,975.

Following the transaction, the number of issued shares (excluding treasury shares) fell to 564.91 million, while treasury shares increased to 2.09 million. Total issued shares remained unchanged at 567.01 million. The latest repurchase represents 0.00443 % of the company’s issued share capital before the event.

Under the general mandate granted on 26 May 2026—which authorises repurchases of up to 56.70 million shares—Essex Bio-Tech has so far bought back 2.09 million shares, equivalent to 0.36896 % of the company’s issued shares at the mandate date. All repurchased shares are being held as treasury stock; none have been cancelled.

In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 16 October 2026. The board confirmed that the buyback complied with all applicable regulations and that all funds due have been duly received.